TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1709239

Group type: EXPERIMENTAL
Intervention: Adrenaline infusion at 0.1 nmol kg‐1 min‐1 (ADR‐L, n=8)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Adrenaline infusion at 0.4 nmol kg‐1 min‐1 (ADR‐H, n=7)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Mental stress (color-word conflict test, CWT, n=10)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Intravenous saline (placebo, n=10)
Number of subjects: 35
Study: 7029696

Group type: EXPERIMENTAL
Intervention: Chlordiazepoxide plus amitriptyline
Number of subjects: 61

Group type: COMPARATOR
Intervention: Maprotiline
Number of subjects: 61
Study: 6543846

Group type: EXPERIMENTAL
Intervention: Medicated nose drops
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Saline nose drops
Number of subjects: 74

Group type: COMPARATOR
Intervention: No nose drops (Control)
Number of subjects: 74
Study: 30464436

Group type: COMPARATOR
Intervention: 490 m
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 2,590 m
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 1,650 m
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Higher altitudes (1,650 m and 2,590 m)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Higher altitudes
Number of subjects: 40
Study: 26343550

Group type: EXPERIMENTAL
Intervention: Glucagon 0.11 to 0.44 mg and 0.33, 0.66 and 1 mg
Number of subjects: 6
Study: 24927691

Group type: EXPERIMENTAL
Intervention: Laparoscopic gastric bypass (LRYGB)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Sleeve gastrectomy (LSG)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Overall (both LRYGB and LSG)
Number of subjects: 14
Study: 23194480

Group type: EXPERIMENTAL
Intervention: Short-term DAPT (3 months)
Number of subjects: 3120

Group type: COMPARATOR
Intervention: Long-term DAPT (12 months)
Number of subjects: 3120
Study: 20044312

Group type: EXPERIMENTAL
Intervention: Self-management intervention
Number of subjects: 223

Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 223
Study: 18606439

Group type: EXPERIMENTAL
Intervention: NAC (neoadjuvant chemotherapy) followed by surgery
Number of subjects: 142

Group type: COMPARATOR
Intervention: Primary surgery
Number of subjects: 142
Study: 16014046

Group type: EXPERIMENTAL
Intervention: Metoprolol 200 mg once daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 12114362

Group type: EXPERIMENTAL
Intervention: Inhaled tobramycin (TOBI), 300 mg, delivered by nebulizer, twice daily, in three 28-day on/28-day off treatment cycles
Number of subjects: 258
Study: 10403163

Group type: EXPERIMENTAL
Intervention: Paroxetine
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study: 7668873

Group type: EXPERIMENTAL
Intervention: Granisetron plus dexamethasone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Granisetron plus hydroxyzine hydrochloride
Number of subjects: 0

Group type: COMPARATOR
Intervention: Granisetron alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Granisetron combined with other antiemetic drugs
Number of subjects: 0
Study: 2205418

Group type: EXPERIMENTAL
Intervention: Thrombolytic treatment with intravenous streptokinase
Number of subjects: 11712

Group type: EXPERIMENTAL
Intervention: Thrombolytic treatment with intravenous streptokinase within 3 hours of onset of symptoms
Number of subjects: 11712

Group type: COMPARATOR
Intervention: Secondary ventricular fibrillation
Number of subjects: 11712
Study: 7449042

Group type: EXPERIMENTAL
Intervention: High Intensity Exercise (HIE)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Light Intensity Exercise (LIE)
Number of subjects: 30
Study: 31336474

Group type: EXPERIMENTAL
Intervention: Educational intervention via SMS
Number of subjects: 160

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 160
Study: 29129611

Group type: EXPERIMENTAL
Intervention: Short sleep condition (SS): 4h/night (2:00-6:00)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control sleep condition (CS): 7h/night (23:00-6:00)
Number of subjects: 16
Study: 27445266

Group type: EXPERIMENTAL
Intervention: Multiplate‐ADP measurements
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Multiplate‐ADP (<50 AUC)
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Fibrinogen levels <2.5 g/L
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Bivariate analysis of body mass index, myocardial infarction, and multiplate‐ADP
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Multivariable linear regression analysis of multiplate‐ADP
Number of subjects: 170
Study: 24089423

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Recreational activity
Number of subjects: 68
Study: 22147444

Group type: EXPERIMENTAL
Intervention: Rituximab (375 mg/m²/week for 4 weeks)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Best available therapy (maintenance or increase in immunosuppressive therapy)
Number of subjects: 24
Study: 19561014

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided TAP block with bupivacaine
Number of subjects: 52

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 52
Study: 17555006

Group type: EXPERIMENTAL
Intervention: Omega-3 fatty acids
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 15811355

Group type: EXPERIMENTAL
Intervention: Estrogen replacement therapy (ERT)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 11318254

Group type: EXPERIMENTAL
Intervention: 5% imiquimod cream applied three times a week
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5% imiquimod cream applied once daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5% imiquimod cream applied twice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5% imiquimod cream applied three times a day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increased dosing frequency (from three times a week to three times a day)
Number of subjects: 0
Study: 9137677

Group type: EXPERIMENTAL
Intervention: Cibenzoline (221 ± 60 mg daily)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Flecainide (165 ± 49 mg daily)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Cibenzoline
Number of subjects: 71

Group type: COMPARATOR
Intervention: Flecainide
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Cibenzoline and Flecainide
Number of subjects: 71
Study: 7955972

Group type: EXPERIMENTAL
Intervention: Islet cell antibodies (ICA) testing in previous GDM patients
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Islet cell antibodies (ICA) positivity
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Insulin autoantibodies (IAA) testing
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: ICA testing in GDM patients
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: ICA-negative patients
Number of subjects: 241
Study: 3555788

Group type: EXPERIMENTAL
Intervention: DAT regimen (daunorubicin 70 mg/m2/day on Days 1‐3, cytarabine 200 mg/m2/day, 6‐thioguanine 200 mg/m2/day)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: TAD regimen (daunorubicin 70 mg/m2/day on Days 5‐7, cytarabine 200 mg/m2/day, 6‐thioguanine 200 mg/m2/day)
Number of subjects: 97
Study: 31340787

Group type: EXPERIMENTAL
Intervention: Breastfeeding Support Programme (BSP)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Control group (no BSP)
Number of subjects: 138
Study: 28425747

Group type: EXPERIMENTAL
Intervention: 10-session psychiatric treatment augmented with the responsive intervention of the motive-oriented therapeutic relationship
Number of subjects: 57

Group type: COMPARATOR
Intervention: 10-session psychiatric treatment
Number of subjects: 57
Study: 25873092

Group type: EXPERIMENTAL
Intervention: Strong EA (high-intensity current 2 mA < current < 5 mA)
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Weak EA (low-intensity current 0 mA < current < 0.5 mA)
Number of subjects: 450

Group type: COMPARATOR
Intervention: Sham EA (low-intensity current 0 mA < current < 0.5 mA, superficial needle insertion)
Number of subjects: 450
Study: 23410714

Group type: COMPARATOR
Intervention: Nonhormonal contraception (NHC)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Etonogestrel implant (ENG-I)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Levonorgestrel intrauterine system (LNG-IUS)
Number of subjects: 24
Study: 21837695

Group type: EXPERIMENTAL
Intervention: Calcitriol with calcium carbonate
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Cholecalciferol with calcium carbonate
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Routine supplementation (calcitriol or cholecalciferol)
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: On-demand supplementation (calcitriol or cholecalciferol)
Number of subjects: 306
Study: 19064985

Group type: COMPARATOR
Intervention: Resistance exercise
Number of subjects: 121

Group type: COMPARATOR
Intervention: Aerobic exercise
Number of subjects: 121

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 121
Study: 16648503

Group type: EXPERIMENTAL
Intervention: Irinotecan 65 mg/m2 IV + cisplatin 30 mg/m2 IV on days 1 and 8 every 21 days
Number of subjects: 331

Group type: COMPARATOR
Intervention: Etoposide 120 mg/m2 IV on days 1 to 3 + cisplatin 60 mg/m2 IV on day 1 every 21 days
Number of subjects: 331

Group type: EXPERIMENTAL
Intervention: Irinotecan/cisplatin
Number of subjects: 331

Group type: COMPARATOR
Intervention: Etoposide/cisplatin
Number of subjects: 331
Study: 14759591

Group type: EXPERIMENTAL
Intervention: Anti-influenza vaccination
Number of subjects: 20
Study: 11706961

Group type: EXPERIMENTAL
Intervention: Corticobasal degeneration
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Steele-Richardson-Olszewski syndrome (SRO)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Multiple system atrophy (MSA)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Idiopathic Parkinson's disease
Number of subjects: 41

Group type: COMPARATOR
Intervention: Matched normals
Number of subjects: 41
Study: 8809212

Group type: EXPERIMENTAL
Intervention: Nitroglycerine administered sublingually
Number of subjects: 14
Study: 1534248

Group type: EXPERIMENTAL
Intervention: Chemotherapy combined with high doses (1000 mg daily) of oral medroxyprogesterone acetate (HD-MPA)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Chemotherapy combined with HD-MPA
Number of subjects: 142
Study: 2408425

Group type: EXPERIMENTAL
Intervention: 1% topical minoxidil
Number of subjects: 23

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study: 30049656

Group type: EXPERIMENTAL
Intervention: Real-time visual CPR feedback device
Number of subjects: 0

Group type: COMPARATOR
Intervention: No feedback (control group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High workload (average score >60)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low workload (average score <60)
Number of subjects: 0
Study: 27379625

Group type: EXPERIMENTAL
Intervention: High-flux hemodialysis (HFHD)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Hemodialysis filtration (HDF)
Number of subjects: 51
Study: 24685956

Group type: EXPERIMENTAL
Intervention: 9-month physical activity intervention (70 minutes, 5 days/week)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 220
Study: 21631592

Group type: EXPERIMENTAL
Intervention: Implant-supported overdentures (IOD)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Implant-supported fixed dental prostheses (IFDP)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Conventional dentures (C/C)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Fully dentate controls (D/D)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Implant-supported prostheses (C/IOD and IFDP/IFDP)
Number of subjects: 80
Study: 18413339

Group type: EXPERIMENTAL
Intervention: Whole-body vibration exercise (5 min, static squat, frequency 30 Hz)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control (no vibration)
Number of subjects: 20
Study: 17659490

Group type: EXPERIMENTAL
Intervention: Interpersonal Psychotherapy (IPT) plus medication
Number of subjects: 124

Group type: COMPARATOR
Intervention: Medication plus Clinical Management
Number of subjects: 124
Study: 15966783

Group type: EXPERIMENTAL
Intervention: Home-based teaching program
Number of subjects: 381

Group type: EXPERIMENTAL
Intervention: Home-based teaching program (subgroup analysis)
Number of subjects: 381
Study: 12393819

Group type: EXPERIMENTAL
Intervention: Breast-conserving surgery (quadrantectomy) followed by radiotherapy
Number of subjects: 701

Group type: COMPARATOR
Intervention: Radical mastectomy
Number of subjects: 701

Group type: EXPERIMENTAL
Intervention: Breast-conserving surgery
Number of subjects: 701
Study: 10330310

Group type: EXPERIMENTAL
Intervention: In-home educational visit by Milwaukee Health Department paraprofessional (n=187)
Number of subjects: 413

Group type: COMPARATOR
Intervention: Reference group (n=226)
Number of subjects: 413

Group type: EXPERIMENTAL
Intervention: In-home educational visit (n=187)
Number of subjects: 413
Study: 8584384

Group type: EXPERIMENTAL
Intervention: DTaP-US
Number of subjects: 189

Group type: COMPARATOR
Intervention: DTaP-J
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: DTaP-US (i.m.)
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: DTaP-US (s.c.)
Number of subjects: 189
Study: 7682927

Group type: EXPERIMENTAL
Intervention: Clomipramine (25 or 50 mg)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Non-active placebo
Number of subjects: 11
Study: 3551051

Group type: EXPERIMENTAL
Intervention: Pankreon granules 20 g per day
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 30174101

Group type: EXPERIMENTAL
Intervention: IANB with intraligamentary injection
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: IANB with buccal injection
Number of subjects: 96

Group type: COMPARATOR
Intervention: IANB alone
Number of subjects: 96
Study: 28590322

Group type: EXPERIMENTAL
Intervention: Off-pump CABG
Number of subjects: 157

Group type: COMPARATOR
Intervention: On-pump CABG
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Arterial grafts
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Vein grafts
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Target territories
Number of subjects: 157
Study: 23636182

Group type: EXPERIMENTAL
Intervention: Bone cement loaded with erythromycin and colistin (study group)
Number of subjects: 2948

Group type: COMPARATOR
Intervention: Bone cement without antibiotic (control group)
Number of subjects: 2948
Study: 21838912

Group type: EXPERIMENTAL
Intervention: Geriatric Monitoring Unit (GMU)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 19289931

Group type: EXPERIMENTAL
Intervention: Chemotherapy or chemotherapy and radiotherapy combination
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Radiotherapy
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Overall immune recovery
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Interferon-gamma, IL-2, IL-4, lymphocyte proliferation, and natural killer cell activity
Number of subjects: 80
Study: 17452584

Group type: EXPERIMENTAL
Intervention: Natalizumab
Number of subjects: 942

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 942
Study: 15090880

Group type: EXPERIMENTAL
Intervention: Intravenous thrombolysis within 3 hours
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intra-arterial thrombolysis within 3-6 hours
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intravenous thrombolysis beyond 3 hours with improved selection criteria
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thrombolysis in general
Number of subjects: 0
Study: 11495257

Group type: EXPERIMENTAL
Intervention: Rifampicin in fixed-dose combination (FDC) anti-tuberculosis formulations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Urinary excretion data
Number of subjects: 0
Study: 9265935

Group type: EXPERIMENTAL
Intervention: Thiopental at 10 micrograms/ml
Number of subjects: 12

Group type: COMPARATOR
Intervention: Fentanyl (1.4 micrograms/kg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Thiopental at 5 and 7.5 micrograms/ml
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 12
Study: 8102107

Group type: EXPERIMENTAL
Intervention: Home elemental enteral hyperalimentation (HEEH)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: HEEH and drugs
Number of subjects: 84

Group type: COMPARATOR
Intervention: Drugs
Number of subjects: 84

Group type: COMPARATOR
Intervention: No maintenance therapy
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Elemental diet (ED) therapy (more than 30 kcal/kg ideal body weight/day)
Number of subjects: 84
Study: 3524428

Group type: EXPERIMENTAL
Intervention: Cefazolin (1 g every 8 h)
Number of subjects: 337

Group type: EXPERIMENTAL
Intervention: Cefamandole (2 g every 6 h)
Number of subjects: 337

Group type: EXPERIMENTAL
Intervention: Cefuroxime (1.5 g every 12 h)
Number of subjects: 337

Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 337

Group type: COMPARATOR
Intervention: Cefazolin
Number of subjects: 337

Group type: EXPERIMENTAL
Intervention: Cefuroxime
Number of subjects: 337

Group type: EXPERIMENTAL
Intervention: Cefamandole
Number of subjects: 337
Study: 30256215

Group type: EXPERIMENTAL
Intervention: Cerebral blood flow velocity (CBFV) measured via transcranial Doppler
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: End-tidal CO2 (EtCO2) measured via capnography
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: RAP (rate of change of arterial pressure)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Systolic blood pressure (BP)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Logistic parameters (y min, y max, k, x) across haemodynamic variables
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: CrCPmin and CrCPmax
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: RAPmin and RAPmax
Number of subjects: 45
Study: 27657520

Group type: EXPERIMENTAL
Intervention: Albuterol MDPI 90 μg
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Albuterol MDPI 180 μg
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Albuterol HFA 180 μg
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Albuterol HFA 90 μg
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 24692735

Group type: EXPERIMENTAL
Intervention: bicalutamide
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: chlormadinone
Number of subjects: 124
Study: 22410389

Group type: EXPERIMENTAL
Intervention: MOVI-2 program (recreational physical activity in after-school time, including two 90-min sessions on weekdays and one 150-min session on Saturdays for one academic year)
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Control group (usual patterns of physical activity)
Number of subjects: 1200

Group type: EXPERIMENTAL
Intervention: MOVI-2 program
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1200
Study: 20307903

Group type: EXPERIMENTAL
Intervention: Alteplase (tPA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Streptokinase
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (no specific control group mentioned)
Number of subjects: 0
Study: 19260368

Group type: EXPERIMENTAL
Intervention: Continuous postoperative analgesia via epidural catheter
Number of subjects: 41

Group type: COMPARATOR
Intervention: Oral and rectal non-steroidal pain-killers
Number of subjects: 41
Study: 15915011

Group type: EXPERIMENTAL
Intervention: Formoterol 12 microg inhaled via HFA-134a inhaler (Modulite HFA)
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: CFC pMDI containing formoterol
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: DPI containing formoterol
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 12891190

Group type: EXPERIMENTAL
Intervention: Primary angioplasty (for half of the 1100 patients transferred from referral hospitals)
Number of subjects: 1900

Group type: COMPARATOR
Intervention: Fibrinolytic therapy (administered immediately at local hospitals)
Number of subjects: 1900
Study: 10574676

Group type: EXPERIMENTAL
Intervention: Preresectional chemotherapy with mitomycin 6 mg/m2, ifosfamide 3 g/m2, and cisplatin 50 mg/m2, given intravenously on day 1 of each cycle at 3-week intervals followed by surgery.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Surgery alone.
Number of subjects: 60
Study: 8686824

Group type: EXPERIMENTAL
Intervention: Clonidine 2 micrograms.kg‐1 intravenously over 10 min after induction of anaesthesia
Number of subjects: 280
Study: 1761240

Group type: EXPERIMENTAL
Intervention: Gynatren (lactobacillus vaccine)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 167
Study: 6282542

Group type: EXPERIMENTAL
Intervention: Disulfiram 250 mg at bedtime
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 30537475

Group type: EXPERIMENTAL
Intervention: Mometasone furoate-formoterol
Number of subjects: 11729

Group type: COMPARATOR
Intervention: Mometasone furoate
Number of subjects: 11729
Study: 29102982

Group type: EXPERIMENTAL
Intervention: Facilitated access to an interactive alcohol reduction website (FA)
Number of subjects: 763

Group type: COMPARATOR
Intervention: Face‐to‐face brief intervention (BI)
Number of subjects: 763
Study: 26449882

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (OXT)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Exposure to favorite brand
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Baseline peripheral OXT concentrations
Number of subjects: 101
Study: 24509938

Group type: EXPERIMENTAL
Intervention: Silicone gel applied to the wound after stitch-out for 1 month
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 100
Study: 22349543

Group type: EXPERIMENTAL
Intervention: Tenotomy/Tenodesis (Group A)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Tenotomy (Group B)
Number of subjects: 65
Study: 19476675

Group type: EXPERIMENTAL
Intervention: Free Fruit and Vegetable Snack (FFVS) + Enhanced Nutrition Education
Number of subjects: 1277

Group type: EXPERIMENTAL
Intervention: FFVS-alone
Number of subjects: 1277

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1277